GlassScriptPhysician profile
Larry W Anderson
NPI 1932157856
$2,210.43
in general payments reported to CMS, 2019-2025
26 companies · $253 in 2025
The $253 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $119 · 2020: $254 · 2021: $299 · 2022: $286 · 2023: $480 · 2024: $519 · 2025: $253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,253.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,252.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $236.39 | 2023-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $232.39 | 2022-2024 | Farxiga, Breztri |
| Edwards Lifesciences Corporation | $212.41 | 2024-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve, Pascal |
| Lilly USA, LLC | $182.51 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Eisai INC. | $179.29 | 2020-2025 | |
| Glaxosmithkline, LLC. | $174.14 | 2021-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $146.40 | 2021-2024 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.25 | 2022-2024 | Ofev |
| Amarin Pharma, INC. | $90.68 | 2019-2021 | |
| Pfizer INC. | $87.32 | 2019-2020 | |
| Grifols USA, LLC | $80.14 | 2020-2024 | Prolastin-C Liquid |
| Novartis Pharmaceuticals Corporation | $70.14 | 2019-2022 | |
| Abbvie INC. | $53.21 | 2022-2023 | Vraylar |
| Idorsia Pharmaceuticals US INC | $49.84 | 2023-2024 | Quviviq |
| Paratek Pharmaceuticals, INC. | $45.51 | 2022-2023 | Nuzyra |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $39.15 | 2022 | |
| Dexcom, INC. | $36.46 | 2022-2024 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $33.74 | 2020 | |
| Astellas Pharma US INC | $27.94 | 2024 | Veozah |
| Phathom Pharmaceuticals, INC. | $25.00 | 2024 | Voquezna |
| Medtronic, INC. | $23.72 | 2025 | Interstim |
| Exact Sciences Corporation | $13.90 | 2024 | Cologuard Collection Kit |
| Hikma Pharmaceuticals USA | $13.73 | 2020 | |
| Genentech USA, INC. | $13.11 | 2020 | |
| Merck Sharp & Dohme LLC | $12.06 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.